Tetra-n-butylammonium fluoride Pharma Grade, product designation TBAF-PG-0429, is supplied as a white to off-white crystalline trihydrate corresponding to the anhydrous CAS registry 429-41-4 and the trihydrate CAS 87749-50-6. The stoichiometric formula C₁₆H₃₆FN·3H₂O has a calculated molecular mass of 315.52 g/mol, with the anhydrous base at 261.47 g/mol. The material is characterized by free water solubility, high organic-solvent compatibility in polar aprotic media, and marked hygroscopicity. These properties define its handling limits in oral solid and parenteral manufacturing. No current Ph. Eur. or USP monograph exists for this quaternary ammonium fluoride; therefore, the release specification is established under ICH Q6A, with validation of analytical procedures according to ICH Q2(R1). The product is processed into tablets, granules, capsules, and injectable solutions after appropriate formulation and, for injections, terminal sterilization. Unlike reagent-grade tetra-n-butylammonium fluoride, the Pharma Grade is controlled for residual solvents under ICH Q3C, elemental impurities under ICH Q3D, microbial quality under Ph. Eur. 5.1.4, and particle size distribution relevant to solid-dosage unit operations.

What Limits Residual Solvent Compliance in Multi-Step Synthesis?

The residual solvent profile is route-dependent. Published preparations frequently involve quaternization of tributylamine with n-butyl bromide or n-butyl chloride, followed by anion exchange with a fluoride source in methanol, acetonitrile, or tetrahydrofuran. Consequently, the Pharma Grade limit is set according to ICH Q3C Option 1. Tetrahydrofuran is controlled at the Class 2 limit of 720 ppm; acetonitrile is controlled at 410 ppm; dichloromethane is controlled at 600 ppm; and methanol is controlled at the Class 2 limit of 3000 ppm. Where a non-ICH-listed solvent is used, a risk assessment under ICH Q3C is required. Gas chromatography with headspace injection is configured with an FID detector and a 624-type capillary column. The method is validated for specificity, linearity, accuracy, and precision according to ICH Q2(R1). Residual solvent failure is a common batch rejection mode when recrystallization from alcohol or THF is not followed by adequate vacuum drying. The product is therefore dried in an agitated vacuum dryer with a jacket temperature not exceeding 35 °C and a final chamber pressure of 10–20 mbar until loss on drying is stable and the trihydrate water content remains within specification by Karl Fischer titration.

The 500 mg maximum daily dose used for ICH Q3D Option 1 is a sponsor-defined specification input; the final drug product may require a lower limit after considering total excipient contributions and the intended route of administration.

Analytical release includes a quaternary ammonium ion purity check by ion chromatography with suppressed conductivity detection. The fluoride counterion is quantified by ion-selective electrode or by ion chromatography after dissolution in deionized water. The assay method is validated for linearity from 80% to 120% of the nominal concentration, accuracy within ±2.0%, and repeatability below 1.0% RSD. Forced degradation studies under acidic, alkaline, oxidative, thermal, and photolytic conditions per ICH Q1B are used to establish peak purity. The material does not require chiral control because tetra-n-butylammonium fluoride is achiral. Polymorphic form is not assigned a separate acceptance criterion, but the crystalline trihydrate is confirmed by X-ray powder diffraction against a reference diffractogram.

Direct compression and dry granulation routes are preferred for this material. Aqueous wet granulation is usually unsuitable because the API dissolves rapidly to form a sticky paste that adheres to high-shear mixer walls; if aqueous binder is required, the binder is added as a premix with the filler and the contact time is kept below 2 min. For capsule filling, the milled powder is blended in a bin blender at 10–12 rpm for 15 min with colloidal silicon dioxide at 0.5–1.0% w/w to reduce moisture uptake. Roller compaction is performed using a side seal and a roll force in the range of 4–8 kN/cm; ribbons are milled through a 1.0 mm screen. Tablet compression on a rotary press requires precompression and main compression forces defined for each formulation; the material is not directly compressible and requires excipients such as microcrystalline cellulose, lactose monohydrate, or dicalcium phosphate dihydrate. Processing rooms are maintained at not more than 35% RH and 20–25 °C. Exposure above 60% RH leads to visible surface wetting and mass gain within 30 min.

Particle Size, Bulk Density, and Flow Characterization for Direct Compression

The milled Pharma Grade is controlled by laser diffraction according to ISO 13320. A typical D10 of 15–25 µm, D50 of 40–60 µm, and D90 of 120–145 µm supports uniform blend content when the active fraction is low. Bulk density by USP <616> Method I is reported on each certificate of analysis; tapped density is determined after 1250 taps. Carr index values above 30 indicate cohesive flow and require granulation or glidant addition. Particle shape by light microscopy is predominantly plate-like with fractured edges after jet milling; rounded particles are not guaranteed unless a spheronized grade is specified.

For injectable preparations, the API is dissolved in Water for Injection at a concentration determined by the final formulation. The resulting solution is not self-preserved and is filtered through a 0.22 µm polyethersulfone or polyvinylidene fluoride membrane before terminal sterilization. Solution pH after dissolution typically ranges between 9.0 and 11.0 due to fluoride hydrolysis; therefore, the formulation is buffered to physiologic pH with phosphate or citrate buffer and osmolarity is adjusted with sodium chloride according to USP <785>. The solution is filled into borosilicate glass vials meeting USP <660>. Terminal sterilization by autoclaving at 121 °C for 15 min is applied. Sterile filtration alone is not considered sufficient unless the final container-closure system is validated for aseptic processing. The API is supplied as a non-sterile crystalline solid; endotoxin control for parenteral use is assigned to the finished product, but the API is tested for bioburden and specified bacterial endotoxins when requested under a parenteral-grade supply agreement.

When Terminal Sterilization of Injectable Solutions Is Required

Because the API is non-sterile at release, all injectable dosage forms must undergo a validated sterilization process. Autoclaving at 121 °C for 15 min is the default cycle for neutral or slightly acidic buffered solutions. For alkaline formulations above pH 9.0, terminal sterilization may accelerate salt hydrolysis and produce free tributylamine; therefore, the finished solution is monitored for amine-related degradation products by headspace gas chromatography with a limit of not more than 0.10% total volatile bases. The container-closure system is selected to resist fluoride attack: borosilicate Type I glass is preferred. Soda-lime-silica glass is not recommended for long-term storage because fluoride can leach silicate and form insoluble particles. Sterile filtration of non-aqueous solutions is not addressed by this specification and requires separate validation.

Differences Relative to Inorganic Fluoride Salts and Reagent-Grade Tetrabutylammonium Fluoride

Tetra-n-butylammonium fluoride differs from sodium fluoride and potassium fluoride in its cation-selective solubility behavior. Sodium fluoride is sparingly soluble in water at approximately 40 g/L at 25 °C and essentially insoluble in polar aprotic solvents, whereas tetra-n-butylammonium fluoride trihydrate is freely soluble in water and soluble in THF, DMF, and acetonitrile. This solubility profile permits fluoride-ion delivery in non-aqueous reaction media but creates a wet-granulation handling constraint not observed with inorganic fluoride salts. Compared with tetra-n-butylammonium bromide, the fluoride salt has a smaller anion radius, stronger hydrogen-bonding capacity, and higher basicity; these properties increase hygroscopicity and require tighter humidity controls. Reagent-grade tetra-n-butylammonium fluoride is commonly supplied as a 1.0 M solution in THF, with water content up to 5% and no microbial or elemental impurity controls. The Pharma Grade described here is supplied as a crystalline solid, not as a solution, and is released with a full ICH-aligned certificate of analysis.

The API is packaged in double polyethylene liners inside a fiber drum or in sealed aluminum laminate pouches under nitrogen. It should be stored in tightly closed containers at 2–8 °C in a desiccated environment; when stored in unopened original packaging below 25 °C, the material should be used within 12 months unless a longer retest period is justified by site stability data. Opened containers for manufacturing campaigns are consumed within a single shift or re-sealed under inert gas. Incompatibilities include strong acids, which generate hydrogen fluoride; oxidizing agents, which may cause exothermic decomposition; and strong bases, which may liberate tributylamine. Mixing with acidic excipients such as citric acid shifts the API toward protonated fluoride species and reduces dissolution reproducibility. For this reason, direct blend formulations are generally buffered to pH 6.0–7.0 to maintain consistent fluoride speciation.